First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
The facility is spread across 215000 sq. feet and provides super-speciality care
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
DR devices today should do more than just provide crystal clear imaging and assist during diagnosis. Hence, the ImageView Software used in DRX Compass offers upgraded cybersecurity
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
Subscribe To Our Newsletter & Stay Updated
